دورية أكاديمية
High Creatinine Level Secondary to Use of CDK 4/6 Inhibitor Treatment (Palbociclib and Ribociclib) + Endocrine Therapy (ET).
| العنوان: | High Creatinine Level Secondary to Use of CDK 4/6 Inhibitor Treatment (Palbociclib and Ribociclib) + Endocrine Therapy (ET). |
|---|---|
| المؤلفون: | Keskinkilic M; Department of Medical Oncology, Dokuz Eylul University, Izmir, Turkiye., Semiz HS; Department of Medical Oncology, Dokuz Eylul University, Izmir, Turkiye., Yavuzsen T; Department of Medical Oncology, Dokuz Eylul University, Izmir, Turkiye., Karaoglu A; Department of Medical Oncology, Dokuz Eylul University, Izmir, Turkiye. |
| المصدر: | Journal of the College of Physicians and Surgeons--Pakistan : JCPSP [J Coll Physicians Surg Pak] 2024 Jul; Vol. 34 (7), pp. 851-853. |
| نوع المنشور: | Journal Article |
| اللغة: | English |
| بيانات الدورية: | Publisher: College of Physicians and Surgeons Pakistan Country of Publication: Pakistan NLM ID: 9606447 Publication Model: Print Cited Medium: Internet ISSN: 1681-7168 (Electronic) Linking ISSN: 1022386X NLM ISO Abbreviation: J Coll Physicians Surg Pak Subsets: MEDLINE |
| أسماء مطبوعة: | Original Publication: Karachi : College of Physicians and Surgeons Pakistan, |
| مواضيع طبية MeSH: | Purines*/adverse effects , Purines*/administration & dosage , Purines*/therapeutic use , Creatinine*/blood , Piperazines*/adverse effects , Piperazines*/administration & dosage , Piperazines*/therapeutic use , Aminopyridines*/adverse effects , Aminopyridines*/administration & dosage , Aminopyridines*/therapeutic use , Pyridines*/adverse effects , Pyridines*/administration & dosage , Cyclin-Dependent Kinase 4*/antagonists & inhibitors, Humans ; Female ; Middle Aged ; Aged ; Breast Neoplasms/drug therapy ; Cyclin-Dependent Kinase 6/antagonists & inhibitors ; Adult ; Protein Kinase Inhibitors/adverse effects ; Protein Kinase Inhibitors/administration & dosage ; Male |
| مستخلص: | The aim of this study is to share real-life data on the increase in creatinine due to CDK 4/6 inhibitor treatment and patients diagnosed with HR+/HER2-MBC and treated with ribociclib or palbociclib combined with ET were included in the study. While creatinine increase was observed in 17.9% (n = 19) of the 106 patients in the study population, 8.5% (n = 9) had Grade 1, 8.5% (n = 8) had Grade 2, and % 0.9 (n = 1) had Grade 3 creatinine elevation. The increase in creatinine occurred in 25% (n = 12) of ribociclib users and 12.1% (n = 7) of palbociclib users. No patient required a dose reduction or discontinuation of treatment due to elevated creatinine. Of the patients with high creatinine levels, 36.8% (n = 7) were over 65 years of age. Those with multiple comorbidities, blood urea nitrogen (BUN) >13.5 mg/dl, creatinine >0.66 mg/dl, BUN/creatinine ratio >19.95, glomerular filtration rate (GFR) >96.05 ml/min, and uric acid >4.69mg/dl. It was observed that the increase in the creatinine level was statistically significant (p <0.001). In conclusion, this study revealed that the increase in the serum creatinine secondary to ribociclib and palbociclib treatments is associated with kidney function tests and the number of concomitant diseases. Key Words: CDK 4/6 inhibitor, Creatinine elevation, Palbociclib, Ribociclib. |
| المشرفين على المادة: | 0 (Purines) TK8ERE8P56 (ribociclib) AYI8EX34EU (Creatinine) 0 (Piperazines) 0 (Aminopyridines) G9ZF61LE7G (palbociclib) 0 (Pyridines) EC 2.7.11.22 (Cyclin-Dependent Kinase 4) EC 2.7.11.22 (Cyclin-Dependent Kinase 6) 0 (Protein Kinase Inhibitors) |
| تواريخ الأحداث: | Date Created: 20240709 Date Completed: 20240709 Latest Revision: 20240726 |
| رمز التحديث: | 20240726 |
| DOI: | 10.29271/jcpsp.2024.07.851 |
| PMID: | 38978255 |
| قاعدة البيانات: | MEDLINE |
| تدمد: | 1681-7168 |
|---|---|
| DOI: | 10.29271/jcpsp.2024.07.851 |